BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 32094355)

  • 1. Altered chromatin landscape and enhancer engagement underlie transcriptional dysregulation in MED12 mutant uterine leiomyomas.
    Moyo MB; Parker JB; Chakravarti D
    Nat Commun; 2020 Feb; 11(1):1019. PubMed ID: 32094355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
    Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
    Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenomic and enhancer dysregulation in uterine leiomyomas.
    Mlodawska OW; Saini P; Parker JB; Wei JJ; Bulun SE; Simon MA; Chakravarti D
    Hum Reprod Update; 2022 Jun; 28(4):518-547. PubMed ID: 35199155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
    Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
    Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
    Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
    Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
    Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
    Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
    Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
    Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
    Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
    Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
    Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
    Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
    Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
    Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.
    Zuberi A; Huang Y; Dotts AJ; Wei H; Coon JS; Liu S; Iizuka T; Wu O; Sotos O; Saini P; Chakravarti D; Boyer TG; Dai Y; Bulun SE; Yin P
    JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37607000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma.
    Berta DG; Kuisma H; Välimäki N; Räisänen M; Jäntti M; Pasanen A; Karhu A; Kaukomaa J; Taira A; Cajuso T; Nieminen S; Penttinen RM; Ahonen S; Lehtonen R; Mehine M; Vahteristo P; Jalkanen J; Sahu B; Ravantti J; Mäkinen N; Rajamäki K; Palin K; Taipale J; Heikinheimo O; Bützow R; Kaasinen E; Aaltonen LA
    Nature; 2021 Aug; 596(7872):398-403. PubMed ID: 34349258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
    Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
    J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
    Schwetye KE; Pfeifer JD; Duncavage EJ
    Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.
    Park MJ; Shen H; Kim NH; Gao F; Failor C; Knudtson JF; McLaughlin J; Halder SK; Heikkinen TA; Vahteristo P; Al-Hendy A; Schenken RS; Boyer TG
    J Clin Endocrinol Metab; 2018 Nov; 103(11):4283-4292. PubMed ID: 30099503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
    Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
    Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
    Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
    Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
    Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
    Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
    Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
    Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
    Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
    PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.